Related Experiment Video
Updated: Mar 1, 2026
08:05
Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence
Published on: June 10, 2025
1.3K
[PROSTATE CANCER EARLY DETECTION USING PSA - CURRENT TRENDS AND RECENT UPDATES].
1Department of Urology, Ha'Emek Medical Center, Afula, Israel.
Harefuah
|May 29, 2017
Summary
Prostate cancer screening using prostate-specific antigen (PSA) tests significantly reduces mortality. However, balancing early detection with risks of overdiagnosis and overtreatment remains a critical challenge in managing this diverse disease.
Area of Science:
- Oncology
- Urology
- Public Health
Background:
- Prostate cancer (Pca) is a leading cause of cancer death in men.
- Prostate-specific antigen (PSA) testing has reduced Pca mortality by 40% since the 1990s.
- Concerns exist regarding overdetection and overtreatment of Pca due to PSA screening.
Purpose of the Study:
- To review the evolution and impact of PSA testing on Pca mortality.
- To address the dilemmas surrounding PSA screening, including overdiagnosis and overtreatment.
- To explore innovations in Pca screening for balanced early detection and treatment.
Main Methods:
- Literature review of PSA testing evolution and its effects.
- Analysis of data on Pca mortality reduction through PSA screening.
- Discussion of current controversies and future directions in Pca screening.
Main Results:
- PSA testing has demonstrated significant efficacy in reducing prostate cancer mortality.
- Overdetection and overtreatment are notable challenges associated with PSA screening.
- There is a need to balance the benefits of early detection against potential harms.
Conclusions:
- PSA screening remains a valuable tool for reducing prostate cancer mortality.
- Strategies are needed to mitigate overdiagnosis and overtreatment while optimizing early detection of aggressive Pca.
- Future innovations aim to refine Pca screening and management approaches.
